Candesartan

Angiotensin II receptor blocker

ATC code: C09CA06

Brand names: Atacand, Amias, Blopress

Updated 29 May 2026 · Methodology

Indications

Heart failure with reduced ejection fraction

First line

Candesartan reduces cardiovascular mortality and hospitalization in heart failure with reduced ejection fraction, as shown in the CHARM program (Lancet 2003): three trials in patients with EF 40 percent or below, including CHARM-Alternative in ACE-inhibitor-intolerant patients. 2023 and NG106 recommend ARBs as an alternative to ACE inhibitors in patients with cough or a history of angioedema.

Sources

ICD-10: I50.1 · ICD-11: BD11.2

Hypertension

First line

Candesartan lowers blood pressure and major cardiovascular events in adults. 2024 and NG136 list ARBs as first-line therapy for hypertension as monotherapy and in combination with a thiazide diuretic or calcium channel blocker. Once-daily dosing with 24-hour effect improves adherence compared with twice-daily losartan.

In patients over 75, start at 4 mg daily. With eGFR below 30 mL/min/1.73 m², start at 4 mg with potassium and creatinine monitoring.

Sources

ICD-10: I10 · ICD-11: BA00

Diabetic nephropathy

First line

ARBs slow the progression of diabetic nephropathy in patients with type 2 diabetes and albuminuria. Pivotal trials are RENAAL (losartan) and IDNT (irbesartan). The DIRECT-Protect 2 trial with candesartan showed a reduction in the progression rate from microalbuminuria to nephropathy. KDIGO 2022 lists ARBs as first-choice agents in patients with albuminuria alongside ACE inhibitors.

Sources

ICD-10: N08.3 · ICD-11: GB61

Migraine prophylaxis

Second line

Candesartan reduces migraine attack frequency by 26 percent versus placebo in the Tronvik RCT (JAMA 2003) at 16 mg daily for 12 weeks. 2019 classifies candesartan at evidence level C: considered as second-line in patients with contraindications to topiramate, propranolol, and amitriptyline, or with co-existing hypertension. Off-label in the Russian Federation.

Sources

ICD-10: G43.9 · ICD-11: 8A80.Z

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

Anti-aging and longevity

Not recommended

Candesartan is an angiotensin II receptor blocker (ARB). It is prescribed for hypertension and heart failure ( 2023, SEH-LELHA, 2017). In anti-aging regimens, candesartan is given to healthy normotensives as a mild protector of the heart and vessels. In people with normal blood pressure, no clinical studies of prophylactic use exist. ARBs do not cause cough as ACE inhibitors do, but other risks remain: hyperkalemia, dizziness, acute kidney injury in renal artery stenosis, and teratogenicity (contraindicated in pregnancy). If candesartan was prescribed to a healthy person, consider seeking a second opinion.

Sources

How to read tiers A–F

AStrong evidence – first or second line in international guidelines
BRecommended in selected cases
CStudy data contradict each other
DBenefit not proven, no documented harm
FDocumented harm, or risk without benefit

Mechanism of action

Selectively blocks AT1 angiotensin II receptors. Reduces blood pressure and left ventricular load. Alternative to ACE inhibitors for cough-intolerant patients.

Safety

Boxed warning

FDA boxed warning: when pregnancy is detected, candesartan is discontinued immediately. Use in the second and third trimesters is associated with oligohydramnios, pulmonary hypoplasia, and fetal renal failure.

Contraindications

Pregnancy
Severe hepatic impairment and/or cholestasis
Bilateral renal artery stenosis or stenosis of a solitary kidney artery
Hyperkalemia above 5.5 mmol/L
Concomitant aliskiren in patients with diabetes or eGFR below 60 mL/min/1.73 m²
Combination with sacubitril/valsartan or with an ACE inhibitor

Serious adverse effects

Angioedema (much less frequent than with ACE inhibitors, less than 0.1 percent)
Acute kidney injury in patients with renal artery stenosis

Common adverse effects

Dizziness, orthostatic hypotension
Headache
Hyperkalemia
Serum creatinine increase
Upper respiratory tract infections

Uncommon adverse effects

Back pain
First-dose hypotension
Neutropenia

Pregnancy: can you take Candesartan?

AEMPS summary of product characteristics (section 4.6): angiotensin II receptor blockers (ARBs) are not recommended in the first trimester and are contraindicated in the second and third trimesters. Evidence on teratogenicity after first-trimester exposure to ACE inhibitors is inconclusive, but a small increase in risk cannot be excluded; there are no controlled epidemiological data for ARBs, though similar risks may exist. Unless continued ARB therapy is considered essential, patients planning a pregnancy should switch to an antihypertensive with an established safety profile in pregnancy; once pregnancy is confirmed, candesartan is stopped immediately and, if appropriate, alternative treatment is started. Second- and third-trimester exposure causes fetal toxicity (reduced renal function, oligohydramnios, delayed skull ossification) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). After exposure from the second trimester onwards, an ultrasound check of renal function and the skull is advised, and infants whose mothers took ARBs are closely watched for hypotension.

Breastfeeding: can you take Candesartan?

Data on candesartan transfer into human milk are limited. LactMed suggests choosing ACE inhibitors (captopril, enalapril) or alternative classes for breastfeeding mothers when therapy is required.

Calculate RID Full profile on NIH LactMed ↗

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Practical notes

Timing and administration

Taken once daily with or without food. Timing is individualized; evening dosing may give additional nocturnal blood pressure reduction in patients with a non-dipping pattern on ambulatory monitoring.

Dose titration

Hypertension start dose is 8 mg daily; after 2–4 weeks raise to 16 mg and, if needed, 32 mg. In patients over 75 and in hepatic impairment, start at 4 mg. In HFrEF the titration is slower: 4 mg → 8 mg → 16 mg → 32 mg in 2-week steps.

Monitoring

Check serum creatinine, potassium, and sodium before starting and 1–2 weeks after initiation or dose increase, then at 1–2 months and every 6–12 months thereafter. With hyperkalemia or a creatinine rise above 30 percent, the drug is held and the cause is investigated.

Special situations

Before surgery under general anesthesia, the morning candesartan dose is usually held: severe hypotension at induction may not respond well to vasopressors. Resume on the first postoperative day with stable hemodynamics. During flu or gastroenteritis with dehydration, the drug is temporarily withheld.

Common myths

Myth: “ARBs cause cancer, especially losartan”. Fact: an meta-analysis in 2018 refuted a link between ARB use and cancer incidence. The 2018–2019 recalls of losartan and valsartan batches concerned N-nitrosodimethylamine impurities at specific manufacturers, not the class.

Myth: “ARBs do not work in Black patients”. Fact: monotherapy is less effective, but combined with a thiazide or calcium channel blocker, ARBs are effective in this population too.

Myth: “candesartan is weaker than losartan”. Fact: at equivalent doses, candesartan provides more stable 24-hour BP control and a larger event reduction in the CHARM heart failure program.

Drug–drug interactions

1 pair found. Sorted from critical to minor.

MajorDiclofenacNon-steroidal anti-inflammatory drugs (NSAIDs)

Mechanism

Similar to ibuprofen + losartan. Diclofenac has a high nephrotoxic potential among NSAIDs.

Symptoms

Reduced urine output, rising creatinine and potassium, oedema. Symptoms appear earlier in older patients and in chronic kidney disease.

Management

Avoid prolonged combination. If diclofenac is needed for a short course, use the minimum effective dose for 5–7 days with creatinine monitoring. For chronic analgesia: paracetamol or celecoxib.

Sources

Pair details →Diclofenac →

Label mentions19 mentions

Verbatim lines from the interaction sections, in the language of the label

From this drug’s label

MajorACE inhibitorsclass named in the label
«Combination Blockade of the Renin-Angiotensin System (RAS): Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of…»
FDA, section 7 · Open on DailyMed
MajorLithium
«Se han descrito aumentos reversibles de las concentraciones séricas de litio y su toxicidad durante la administración concomitante de litio con inhibidores de la ECA. Un efecto similar puede…»
AEMPS, section 4.5 · Open on CIMA
ModerateAINEclass named in the label
«Al igual que ocurre con los inhibidores de la ECA, el uso concomitante de ARA-II y AINEs, puede provocar un aumento del riesgo de empeoramiento de la función renal, incluyendo una posible…»
AEMPS, section 4.5 · Open on CIMA
ModerateCo-trimoxazole
«Hiperpotasemia: El uso concomitante de candesartán y diuréticos ahorradores de potasio, suplementos de potasio, sustitutos de la sal que contengan potasio u otros medicamentos que puedan incrementar…»
AEMPS, section 4.4 · Open on CIMA
Moderatediuréticos ahorradores de potasioclass named in the label
«Hiperpotasemia: El uso concomitante de candesartán y diuréticos ahorradores de potasio, suplementos de potasio, sustitutos de la sal que contengan potasio u otros medicamentos que puedan incrementar…»
AEMPS, section 4.4 · Open on CIMA
ModerateLithium
«Lithium: Increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists, including candesartan…»
FDA, section 7 · Open on DailyMed
ModerateNSAIDsclass named in the label
«Lithium: In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors…»
FDA, section 7 · Open on DailyMed
Moderatepotassium supplementsclass named in the label
«Agents Increasing Serum Potassium: Co-administration of candesartan cilexetil with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise…»
FDA, section 7 · Open on DailyMed
ModerateSpironolactone
«Hiperpotasemia: Puede producirse hiperpotasemia en pacientes con insuficiencia cardíaca tratados con candesartán.. Se recomienda el control periódico de potasio sérico. No se recomienda la…»
AEMPS, section 4.4 · Open on CIMA
Moderatesuplementos de potasioclass named in the label
«Hiperpotasemia: El uso concomitante de candesartán y diuréticos ahorradores de potasio, suplementos de potasio, sustitutos de la sal que contengan potasio u otros medicamentos que puedan incrementar…»
AEMPS, section 4.4 · Open on CIMA
anticonceptivos hormonalesclass named in the label
«hidroclorotiazida, warfarina, digoxina, anticonceptivos orales, (etinilestradiol/levonorgestrel), glibenclamida, nifedipino y enalapril. No se han identificado interacciones farmacocinéticas…»
AEMPS, section 4.5 · Open on CIMA
Digoxin
«hidroclorotiazida, warfarina, digoxina, anticonceptivos orales, (etinilestradiol/levonorgestrel), glibenclamida, nifedipino y enalapril. No se han identificado interacciones farmacocinéticas…»
AEMPS, section 4.5 · Open on CIMA
Enalapril
«hidroclorotiazida, warfarina, digoxina, anticonceptivos orales, (etinilestradiol/levonorgestrel), glibenclamida, nifedipino y enalapril. No se han identificado interacciones farmacocinéticas…»
AEMPS, section 4.5 · Open on CIMA
Ethinylestradiol
«hidroclorotiazida, warfarina, digoxina, anticonceptivos orales, (etinilestradiol/levonorgestrel), glibenclamida, nifedipino y enalapril. No se han identificado interacciones farmacocinéticas…»
AEMPS, section 4.5 · Open on CIMA
Glibenclamide
«hidroclorotiazida, warfarina, digoxina, anticonceptivos orales, (etinilestradiol/levonorgestrel), glibenclamida, nifedipino y enalapril. No se han identificado interacciones farmacocinéticas…»
AEMPS, section 4.5 · Open on CIMA
Hydrochlorothiazide
«hidroclorotiazida, warfarina, digoxina, anticonceptivos orales, (etinilestradiol/levonorgestrel), glibenclamida, nifedipino y enalapril. No se han identificado interacciones farmacocinéticas…»
AEMPS, section 4.5 · Open on CIMA
Levonorgestrel
«hidroclorotiazida, warfarina, digoxina, anticonceptivos orales, (etinilestradiol/levonorgestrel), glibenclamida, nifedipino y enalapril. No se han identificado interacciones farmacocinéticas…»
AEMPS, section 4.5 · Open on CIMA
Nifedipine
«hidroclorotiazida, warfarina, digoxina, anticonceptivos orales, (etinilestradiol/levonorgestrel), glibenclamida, nifedipino y enalapril. No se han identificado interacciones farmacocinéticas…»
AEMPS, section 4.5 · Open on CIMA
Warfarin
«hidroclorotiazida, warfarina, digoxina, anticonceptivos orales, (etinilestradiol/levonorgestrel), glibenclamida, nifedipino y enalapril. No se han identificado interacciones farmacocinéticas…»
AEMPS, section 4.5 · Open on CIMA

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Candesartan used for?

Candesartan is evaluated for the following indications with varying evidence strength: Hypertension (evidence tier A), Heart failure with reduced ejection fraction (evidence tier A), Migraine prophylaxis (evidence tier B). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Candesartan?

Common side effects of Candesartan (≥ 1 in 100): Dizziness, orthostatic hypotension, Headache, Hyperkalemia, Serum creatinine increase, Upper respiratory tract infections. See the Safety section for uncommon and serious reactions.

Is Candesartan safe during pregnancy?

Is Candesartan compatible with breastfeeding?

Data on candesartan transfer into human milk are limited. LactMed suggests choosing ACE inhibitors (captopril, enalapril) or alternative classes for breastfeeding mothers when therapy is required.

Who should not take Candesartan?

Candesartan is contraindicated in: Pregnancy; Severe hepatic impairment and/or cholestasis; Bilateral renal artery stenosis or stenosis of a solitary kidney artery; Hyperkalemia above 5.5 mmol/L; Concomitant aliskiren in patients with diabetes or eGFR below 60 mL/min/1.73 m². Full list in the Safety section.

Does Candesartan carry an FDA boxed warning?

“ARBs cause cancer, especially losartan”

an FDA meta-analysis in 2018 refuted a link between ARB use and cancer incidence. The 2018–2019 recalls of losartan and valsartan batches concerned N-nitrosodimethylamine impurities at specific manufacturers, not the class.

“ARBs do not work in Black patients”

monotherapy is less effective, but combined with a thiazide or calcium channel blocker, ARBs are effective in this population too.

“candesartan is weaker than losartan”

at equivalent doses, candesartan provides more stable 24-hour BP control and a larger event reduction in the CHARM heart failure program.

Official sources

Direct links to regulator labels. Open in a new tab.

AEMPS / CIMALabel dated 03/26/2025
FDA / DailyMedLabel dated 02/05/2026
GRLS

Other drugs in this group

Candesartan + Hydrochlorothiazide, Captopril, Enalapril, Enalapril + Hydrochlorothiazide, Irbesartan, Olmesartan medoxomil, Telmisartan, Amlodipine + Olmesartan + Hydrochlorothiazide